Results 131 to 140 of about 614 (173)

Torsade de pointes associated with elevated N-acetylprocainamide levels

American Heart Journal, 1985
N-acetylprocainamide (NAPA), the major metabolite of procainamide, has been shown to have separate antiarrhythmic and side effects from procainamide.l Torsade de pointes, a type of polymorphous ventricular tachycardia characterized by “twisting” of ventricular complexes around the isoelectric line and usually associated with QT prolongation,2 has been ...
H G, Stratmann, K E, Walter, H L, Kennedy   +2 more
openaire   +2 more sources

Antiarrhythmic potency of procainamide and N-acetylprocainamide in rabbits

European Journal of Pharmacology, 1978
The antiarrhythmic potency of procainamide (PA) and N-acetylprocainamide (NAPA) has been investigated in rabbits using isolated atrial preparations and ouabain-induced ventricular fibrillation in vivo. At concentrations in the range 3 x 10(-5) to 1 x 10(-3) M, both PA and NAPA decreased the maximum following frequency (MFF) of isolated atria. The dose--
Minchin, Rodney F., Ilett, Kenneth F., Paterson, James W.   +2 more
openaire   +3 more sources

Procainamide, N-Acetylprocainamide, Antinuclear Antibody and Systemic Lupus Erythomatosus

Angiology, 1986
Long-term therapy with procainamide (PA) leads to the systemic lupus erythematosus syndrome (SLE) in about 30% of patients and 80% develop antinuclear antibodies. Acetylation of procainamide results in the formation of N-acetylprocainamide (NAPA) the propensity of which to induce SLE and to increase antinuclear antibodies is negligible while its ...
M M, Reidenberg, D E, Drayer
openaire   +2 more sources

N-Acetylprocainamide's Antiarrhythmic Action in Patients with Ventricular Tachycardia

Angiology, 1986
Antiarrhythmic properties of N-acetylprocainamide, an active metabolite of procainamide, were studied in 15 patients who presented with a cardiac arrest or documented sustained ventricular tachycardia. Programmed electrical stimulation studies were performed.
J, Somberg, J, Wynn, D, Miura, V, Torres, S, Williams, D, Keefe   +5 more
openaire   +2 more sources

Effect kinetics of N-acetylprocainamide-induced QT interval prolongation

Clinical Pharmacology and Therapeutics, 1987
We attempted to correlate clinical response with the effects of N-acetylprocainamide (NAPA) on the QT interval in five patients with stable chronic ventricular arrhythmias. A 15 mg/kg dose of NAPA was administered and a pharmacokinetic-pharmacodynamic model was used to relate plasma NAPA concentrations to changes in corrected QT interval (QTc).
A A, Piergies, T I, Ruo, E M, Jansyn, S M, Belknap, A J, Atkinson   +4 more
openaire   +2 more sources

N-Acetylprocainamide kinetics after single and repeated oral doses

Clinical Pharmacology and Therapeutics, 1982
The kinetic behavior of N-acetylprocainamide (NAPA) was studied after single and repeated oral doses in six healthy subjects and five patients with cardiomyopathy. Renal clearance (CLR) of NAPA was lower in patients than in normal subjects after an initial 1-gm dose (1.3 +/- 0.4 [x +1- SD] and 2.7 +/- 0.4 ml . min-1 .
T M, Ludden, M H, Crawford
openaire   +2 more sources

N-acetylprocainamide and ischemia-induced ventricular fibrillation in the dog

European Journal of Pharmacology, 1979
Open-chest dogs anesthetized with pentobarbital were treated with saline or N-acetylprocainamide (20 mg/kg, i.v.) 10 min prior to simultaneous ligation of the left anterior descending and septal coronary arteries. Ventricular fibrillation occurred in 20 of 26 control dogs but in only 6 of 15 dogs treated with N-acetylprocainamide (P less than 0.05 ...
R D, Reynolds, B L, Kamath
openaire   +2 more sources

Clinical Evaluation of the EMIT® Procainamide and N-Acetylprocainamide Assay

Therapeutic Drug Monitoring, 1979
Procainamide and its major metabolite, N-acetylprocainamide, were measured by the homogeneous enzyme immunoassay technique (EMIT). The reagents for the EMIT assays were supplied as a separate matched set for each assay. There is no cross-reactivity by procainamide in the assay for N-acetylprocainamide or by N-acetylprocainamide in the assay for ...
C B, Walberg, S H, Wan
openaire   +2 more sources

Acecainide (N-Acetylprocainamide)

Drugs, 1990
Acecainide (N-acetylprocainamide), the N-acetylated metabolite of procainamide, is a Class III antiarrhythmic agent. It can be given either intravenously or orally, and is eliminated primarily by renal excretion. In a small number of noncomparative and placebo-controlled short term therapeutic trials acecainide markedly reduced premature ventricular ...
D W, Harron, R N, Brogden
openaire   +2 more sources

Kinetic Analysis of the Vasodilator and Ganglionic Blocking Actions of N-Acetylprocainamide

Journal of Cardiovascular Pharmacology, 1982
The hypotensive effects of N-acetylprocainamide (NAPA) were studied in anesthetized dogs and in a normal subject. In dogs, intravenous NAPA infusions reduced mean arterial pressure and the pressor response of the isolated, perfused gracilis muscle vascular bed to preganglionic, but not postganglionic, sympathetic stimulation.
J R, Eudeikis, T K, Henthorn, J J, Lertora, A J, Atkinson, G C, Chao, W, Kushner   +5 more
openaire   +2 more sources